Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Factors associated with improved toxicity and tolerability of intraperitoneal chemotherapy in advanced-stage epithelial ovarian cancers.

Teefey P, Bou Zgheib N, Apte SM, Gonzalez-Bosquet J, Judson PL, Roberts WS, Lancaster JM, Wenham RM.

Am J Obstet Gynecol. 2013 Jun;208(6):501.e1-7. doi: 10.1016/j.ajog.2013.03.012. Epub 2013 Mar 15.

PMID:
23507546
2.

Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.

Barlin JN, Dao F, Bou Zgheib N, Ferguson SE, Sabbatini PJ, Hensley ML, Bell-McGuinn KM, Konner J, Tew WP, Aghajanian C, Chi DS.

Gynecol Oncol. 2012 Jun;125(3):621-4. doi: 10.1016/j.ygyno.2012.03.027. Epub 2012 Mar 21.

PMID:
22446622
3.

Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.

Nagao S, Iwasa N, Kurosaki A, Nishikawa T, Ohishi R, Hasegawa K, Goto T, Fujiwara K.

Int J Gynecol Cancer. 2012 Jan;22(1):70-5. doi: 10.1097/IGC.0b013e318234f927.

PMID:
22146766
4.

Safety and outcome of patients treated with a modified outpatient intraperitoneal regimen for epithelial ovarian, primary peritoneal or fallopian tube cancer.

Battelli C, Campo M, Buss MK, Awtrey CS, Konstantinopoulos PA.

Chemotherapy. 2013;59(4):251-9. doi: 10.1159/000356758. Epub 2014 Jan 17.

PMID:
24457572
5.

[Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].

Ma Y, Li Y, Cui H, Liang XD, Tang ZJ, Li XP, Zhao Y, Wei LH.

Zhonghua Fu Chan Ke Za Zhi. 2012 May;47(5):355-60. Chinese.

PMID:
22883524
6.

An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.

Berry E, Matthews KS, Singh DK, Buttin BM, Lurain JR, Alvarez RD, Schink J.

Gynecol Oncol. 2009 Apr;113(1):63-7. doi: 10.1016/j.ygyno.2008.12.035. Epub 2009 Feb 7.

PMID:
19201457
7.

Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study.

Dizon DS, Sill MW, Gould N, Rubin SC, Yamada SD, Debernardo RL, Mannel RS, Eisenhauer EL, Duska LR, Fracasso PM.

Gynecol Oncol. 2011 Nov;123(2):182-6. doi: 10.1016/j.ygyno.2011.07.016. Epub 2011 Aug 5.

8.

Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.

Esselen KM, Rodriguez N, Growdon W, Krasner C, Horowitz NS, Campos S.

Gynecol Oncol. 2012 Oct;127(1):51-4. doi: 10.1016/j.ygyno.2012.05.026. Epub 2012 May 30.

PMID:
22659193
9.

Feasibility of a modified outpatient regimen of intravenous/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients: a GEICO study.

Oaknin A, Roda D, González-Martín A, Chiva L, García-Donas J, de Juan A, Redondo A, Martínez S, García Y, Catot S, Ponce J, Del Campo JM, Cervantes A, Poveda A.

Int J Gynecol Cancer. 2011 Aug;21(6):1048-55. doi: 10.1097/IGC.0b013e31821ee777.

PMID:
21738038
10.

Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.

Skarlos DV, Aravantinos G, Kosmidis P, Athanassiadis A, Stathopoulos GP, Pavlidis N, Bafaloukos D, Karphathios S, Papakostas P, Bamia C, Fountzilas G.

Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-57-S15-61.

PMID:
9346224
11.

Feasibility and safety of a modified outpatient regimen with intravenous/intraperitoneal chemotherapy for optimally debulked stage III ovarian cancer.

Bruixola G, Domingo S, Díaz R, Caballero J, Palomar L, De La Cueva H, Santaballa A.

Int J Gynecol Cancer. 2015 Feb;25(2):214-21. doi: 10.1097/IGC.0000000000000330.

PMID:
25415075
12.
13.

Outpatient platinum-taxane intraperitoneal chemotherapy regimen for ovarian cancer.

Seamon LG, Carlson MJ, Richardson DL, Cohn DE, Fowler JM, Copeland LJ, O'Malley DM.

Int J Gynecol Cancer. 2009 Oct;19(7):1195-8. doi: 10.1111/IGC.0b013e3181b33d5b.

PMID:
19823054
14.

A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer.

Bouchard-Fortier G, Rosen B, Vyarvelska I, Pasetka M, Covens A, Gien LT, Kupets R, Pulman K, Ferguson SE, Vicus D.

Gynecol Oncol. 2016 Jan;140(1):36-41. doi: 10.1016/j.ygyno.2015.11.005. Epub 2015 Nov 4.

PMID:
26546964
15.

A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study.

Tiersten AD, Sill MW, Knight D, Muggia F, Garcia AA, Swensen R, Warshal DP, Mannel RS, Fracasso PM.

Gynecol Oncol. 2010 Sep;118(3):303-7. doi: 10.1016/j.ygyno.2010.05.020. Epub 2010 Jun 14.

16.

Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study.

Chang YH, Lu CH, Yen MS, Lee WH, Chang Y, Chang WP, Chuang CM.

Chin J Cancer. 2016 May 9;35:45. doi: 10.1186/s40880-016-0105-3.

17.

Future directions in the chemotherapy of ovarian cancer.

Ozols RF.

Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-86-S15-90. Review.

PMID:
9346230
18.

A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.

Abaid LN, Micha JP, Rettenmaier MA, Brown JV, Mendivil AA, Lopez KL, Goldstein BH.

Cancer Chemother Pharmacol. 2013 Jul;72(1):101-7. doi: 10.1007/s00280-013-2173-2. Epub 2013 May 10.

PMID:
23660691
19.

Increased incidence of severe gastrointestinal events with first-line paclitaxel, carboplatin, and vorinostat chemotherapy for advanced-stage epithelial ovarian, primary peritoneal, and fallopian tube cancer.

Mendivil AA, Micha JP, Brown JV 3rd, Rettenmaier MA, Abaid LN, Lopez KL, Goldstein BH.

Int J Gynecol Cancer. 2013 Mar;23(3):533-9. doi: 10.1097/IGC.0b013e31828566f1.

PMID:
23385285
20.

Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study.

Spriggs DR, Brady MF, Vaccarello L, Clarke-Pearson DL, Burger RA, Mannel R, Boggess JF, Lee RB, Hanly M.

J Clin Oncol. 2007 Oct 1;25(28):4466-71.

PMID:
17906207

Supplemental Content

Support Center